In vitro studies indicated IP-10 is rapidly and robustly expressed by airway epithelia upon exposure to bacterial pathogens, supporting results in the clinic and suggesting that IP-10 may serve as a sensitive and dynamic biomarker of APE in CF, and possibly other airway diseases. This evidence concerns the gene CXCL10 and apparent mineralocorticoid excess.